UNSPSC 51142025: Ethoheptazine

This classification denotes an opioid receptor agonist with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3A4G3A848U, chemically known as 1H-Azepine-4-carboxylic acid, hexahydro-1-methyl-4-phenyl-, ethyl ester but generally known as ethoheptazine, which bears US NIH Compound Identifier 6469. European Medicines Agency schedules ethoheptazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07280MIG. Most nations schedule ethoheptazine under HS 29339930 and SITC 51577.

As of Q4 2014, ETHOHEPTAZINE remains the US FDA Preferred Term for this commodity. Ethoheptazine bears US NLM identifiers UMLS ID C0059725 and NCI Concept Code C76840. SMILES: CCOC(=O)C1(CCCN(CC1)C)C2=CC=CC=C2.

UNSPSC 51142025 Ethoheptazine, a Commodity code, does not reflect the actual work state and local governments are buying under this classification. The recent solicitations tagged to this code cover naloxone and drug deactivation systems, direct-to-manufacturer pharmaceutical distribution, and generic multi-source pharmaceuticals and over-the-counter products—none of which are ethoheptazine, a Schedule II opioid analgesic with limited modern use. State and local health departments, benefits programs, and cooperative purchasing alliances are using this code to solicit pharmaceutical supplies and pharmacy benefit management services, but the code assignment appears misaligned with procurement reality. The issuing bodies span state health and human services commissions, county public health operations, and multistate cooperative purchasing consortia, reflecting the fragmentation of pharmacy procurement across health systems and self-insured benefit programs.

Geographic activity centers on Florida, Texas, and Minnesota. Seminole County, Florida (IFB 60459723LAS, due July 26, 2023) solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local jurisdictions, with proposals due March 26, 2026. The code shows low relevant activity and a significant mismatch between nominal scope and actual procurement, suggesting either consistent miscoding by issuing bodies or discontinuation of ethoheptazine as a state and local procurement line item.